These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 37887566)

  • 1. Evaluation of Anti-Mullerian Hormone Levels, Antral Follicle Counts, and Mean Ovarian Volumes in Chemotherapy-Induced Amenorrhea among Breast Cancer Patients: A Prospective Clinical Study.
    Ünal Ç; Ordu Ç; Özmen T; İlgun AS; Çelebi F; Baysal B; Özkurt E; Duymaz T; Erdoğan İyigün Z; Kurt S; Öztürk MA; Pilancı KN; Alço G; Yararbaş K; Kayan Tapan T; Güven DC; Soybir G; Özmen V
    Curr Oncol; 2023 Oct; 30(10):9217-9229. PubMed ID: 37887566
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protective effect of goserelin on ovarian reserve during (neo)adjuvant chemotherapy in young breast cancer patients: a prospective cohort study in China.
    Wang S; Pei L; Hu T; Jia M; Wang S
    Hum Reprod; 2021 Mar; 36(4):976-986. PubMed ID: 33411897
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reduced ovarian reserve in young early breast cancer patients: preliminary data from a prospective cohort trial.
    Wenners A; Grambach J; Koss J; Maass N; Jonat W; Schmutzler A; Mundhenke C
    BMC Cancer; 2017 Sep; 17(1):632. PubMed ID: 28877720
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-Mullerian hormone, inhibin B, and antral follicle count in young women with ovarian failure.
    Knauff EA; Eijkemans MJ; Lambalk CB; ten Kate-Booij MJ; Hoek A; Beerendonk CC; Laven JS; Goverde AJ; Broekmans FJ; Themmen AP; de Jong FH; Fauser BC;
    J Clin Endocrinol Metab; 2009 Mar; 94(3):786-92. PubMed ID: 19066296
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antimullerian hormone and inhibin B are hormone measures of ovarian function in late reproductive-aged breast cancer survivors.
    Su HI; Sammel MD; Green J; Velders L; Stankiewicz C; Matro J; Freeman EW; Gracia CR; DeMichele A
    Cancer; 2010 Feb; 116(3):592-9. PubMed ID: 19918920
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chemotherapy-induced ovarian failure in young women with early breast cancer: Prospective analysis of four randomised neoadjuvant/adjuvant breast cancer trials.
    Furlanetto J; Marmé F; Seiler S; Thode C; Untch M; Schmatloch S; Schneeweiss A; Bassy M; Fasching PA; Strik D; Stickeler E; Schem C; Karn T; Grischke EM; Denkert C; van Mackelenbergh M; Müller V; Nekljudova V; Loibl S
    Eur J Cancer; 2021 Jul; 152():193-203. PubMed ID: 34116270
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Age, anti-müllerian hormone, antral follicles count to predict amenorrhea or oligomenorrhea after chemotherapy with cyclophosphamide.
    D'Avila ÂM; Biolchi V; Capp E; Corleta Hv
    J Ovarian Res; 2015 Dec; 8():82. PubMed ID: 26667243
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-Müllerian hormone versus antral follicle count for defining the starting dose of FSH.
    Lan VT; Linh NK; Tuong HM; Wong PC; Howles CM
    Reprod Biomed Online; 2013 Oct; 27(4):390-9. PubMed ID: 23953069
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Individualized FSH dosing based on ovarian reserve testing in women starting IVF/ICSI: a multicentre trial and cost-effectiveness analysis.
    van Tilborg TC; Oudshoorn SC; Eijkemans MJC; Mochtar MH; van Golde RJT; Hoek A; Kuchenbecker WKH; Fleischer K; de Bruin JP; Groen H; van Wely M; Lambalk CB; Laven JSE; Mol BWJ; Broekmans FJM; Torrance HL;
    Hum Reprod; 2017 Dec; 32(12):2485-2495. PubMed ID: 29121350
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A pilot study of predictive markers of chemotherapy-related amenorrhea among premenopausal women with early stage breast cancer.
    Anders C; Marcom PK; Peterson B; Gu L; Unruhe S; Welch R; Lyons P; Behera M; Copland S; Kimmick G; Shaw H; Snyder S; Antenos M; Woodruff T; Blackwell K
    Cancer Invest; 2008; 26(3):286-95. PubMed ID: 18317970
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Which is more predictive ovarian sensitivity marker if there is discordance between serum anti-Müllerian hormone levels and antral follicle count? A retrospective analysis.
    Aslan K; Kasapoglu I; Cakir C; Koc M; Celenk MD; Ata B; Avci B; Uncu G
    J Obstet Gynaecol; 2022 Jul; 42(5):1461-1466. PubMed ID: 34996328
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pretreatment anti-Müllerian hormone predicts for loss of ovarian function after chemotherapy for early breast cancer.
    Anderson RA; Rosendahl M; Kelsey TW; Cameron DA
    Eur J Cancer; 2013 Nov; 49(16):3404-11. PubMed ID: 23968732
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlation of Follicle-stimulating Hormone, Anti-Mullerian Hormone, and Antral Follicle Count with Age in Ovarian Reserve Testing.
    Das S; Bhattacharya N; Mahata R; Ghosh S; Bhar AS; Srivastava P
    Int J Appl Basic Med Res; 2024; 14(3):162-168. PubMed ID: 39310079
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interactions between serum FSH, inhibin B and antral follicle count in the decline of serum AMH during the menstrual cycle in late reproductive age.
    Robertson DM; Lee CH; Baerwald A
    Endocrinol Diabetes Metab; 2021 Apr; 4(2):e00172. PubMed ID: 33855196
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ovarian reserve after treatment with alkylating agents during childhood.
    Thomas-Teinturier C; Allodji RS; Svetlova E; Frey MA; Oberlin O; Millischer AE; Epelboin S; Decanter C; Pacquement H; Tabone MD; Sudour-Bonnange H; Baruchel A; Lahlou N; De Vathaire F
    Hum Reprod; 2015 Jun; 30(6):1437-46. PubMed ID: 25801499
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Functional ovarian reserve in transgender men receiving testosterone therapy: evidence for preserved anti-Müllerian hormone and antral follicle count under prolonged treatment.
    Yaish I; Tordjman K; Amir H; Malinger G; Salemnick Y; Shefer G; Serebro M; Azem F; Golani N; Sofer Y; Stern N; Greenman Y
    Hum Reprod; 2021 Sep; 36(10):2753-2760. PubMed ID: 34411251
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pretreatment serum anti-müllerian hormone predicts long-term ovarian function and bone mass after chemotherapy for early breast cancer.
    Anderson RA; Cameron DA
    J Clin Endocrinol Metab; 2011 May; 96(5):1336-43. PubMed ID: 21325458
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discordance between serum anti-Müllerian hormone concentrations and antral follicle counts: not only technical issues.
    Alebic MŠ; Stojanovic N; Dewailly D
    Hum Reprod; 2018 Jun; 33(6):1141-1148. PubMed ID: 29688494
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the influence of three fibroid treatment options: supracervical hysterectomy, ulipristal acetate and uterine artery embolization on ovarian reserve - an observational study.
    Czuczwar P; Stepniak A; Milart P; Paszkowski T; Wozniak S
    J Ovarian Res; 2018 Jun; 11(1):45. PubMed ID: 29859107
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-müllerian hormone compared with other ovarian markers after childhood cancer treatment.
    Nyström A; Mörse H; Nordlöf H; Wiebe K; Artman M; Øra I; Giwercman A; Henic E; Elfving M
    Acta Oncol; 2019 Feb; 58(2):218-224. PubMed ID: 30558460
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.